Vertex Pharmaceuticals and Tibotec Announce Start of Phase 3 'ADVANCE' Study of Telaprevir

[Guest guest]

Vertex Pharmaceuticals and Tibotec Announce Start of Phase 3 'ADVANCE' Stud..

PharmaLive News Archive - 12-Mar-2008

Telaprevir is the most advanced HCV protease inhibitor in clinical development

targeting treatment of hepatitis C, a disease that afflicts more than 3 million

people in the United States alone, and 170 million worldwide. In this study,

rapid viral response (RVR) criteria will be used to determine which telaprevir

patients can stop all treatment at 24 weeks.

Summary

• Telaprevir is the most advanced HCV protease inhibitor in clinical development

targeting treatment of hepatitis C, a disease that afflicts more than 3 million

people in the United States alone, and 170 million worldwide.

• The ADVANCE trial will enroll 1,050 treatment-naive genotype 1 HCV patients

and will evaluate two 24-week telaprevir-based regimens in comparison to a

48-week control arm.

• The primary endpoint of the study is sustained viral response (SVR), defined

as undetectable HCV RNA (

_________________________________________________________________

Climb to the top of the charts! Play the word scramble challenge with star

power.

http://club.live.com/star_shuffle.aspx?icid=starshuffle_wlmailtextlink_jan

[Guest guest]

Vertex Pharmaceuticals and Tibotec Announce Start of Phase 3 'ADVANCE' Stud..

PharmaLive News Archive - 12-Mar-2008

Telaprevir is the most advanced HCV protease inhibitor in clinical development

targeting treatment of hepatitis C, a disease that afflicts more than 3 million

people in the United States alone, and 170 million worldwide. In this study,

rapid viral response (RVR) criteria will be used to determine which telaprevir

patients can stop all treatment at 24 weeks.

Summary

• Telaprevir is the most advanced HCV protease inhibitor in clinical development

targeting treatment of hepatitis C, a disease that afflicts more than 3 million

people in the United States alone, and 170 million worldwide.

• The ADVANCE trial will enroll 1,050 treatment-naive genotype 1 HCV patients

and will evaluate two 24-week telaprevir-based regimens in comparison to a

48-week control arm.

• The primary endpoint of the study is sustained viral response (SVR), defined

as undetectable HCV RNA (

_________________________________________________________________

Climb to the top of the charts! Play the word scramble challenge with star

power.

http://club.live.com/star_shuffle.aspx?icid=starshuffle_wlmailtextlink_jan

[Guest guest]

Vertex Pharmaceuticals and Tibotec Announce Start of Phase 3 'ADVANCE' Stud..

PharmaLive News Archive - 12-Mar-2008

Telaprevir is the most advanced HCV protease inhibitor in clinical development

targeting treatment of hepatitis C, a disease that afflicts more than 3 million

people in the United States alone, and 170 million worldwide. In this study,

rapid viral response (RVR) criteria will be used to determine which telaprevir

patients can stop all treatment at 24 weeks.

Summary

• Telaprevir is the most advanced HCV protease inhibitor in clinical development

targeting treatment of hepatitis C, a disease that afflicts more than 3 million

people in the United States alone, and 170 million worldwide.

• The ADVANCE trial will enroll 1,050 treatment-naive genotype 1 HCV patients

and will evaluate two 24-week telaprevir-based regimens in comparison to a

48-week control arm.

• The primary endpoint of the study is sustained viral response (SVR), defined

as undetectable HCV RNA (

_________________________________________________________________

Climb to the top of the charts! Play the word scramble challenge with star

power.

http://club.live.com/star_shuffle.aspx?icid=starshuffle_wlmailtextlink_jan

[Guest guest]

Vertex Pharmaceuticals and Tibotec Announce Start of Phase 3 'ADVANCE' Stud..

PharmaLive News Archive - 12-Mar-2008

Telaprevir is the most advanced HCV protease inhibitor in clinical development

targeting treatment of hepatitis C, a disease that afflicts more than 3 million

people in the United States alone, and 170 million worldwide. In this study,

rapid viral response (RVR) criteria will be used to determine which telaprevir

patients can stop all treatment at 24 weeks.

Summary

• Telaprevir is the most advanced HCV protease inhibitor in clinical development

targeting treatment of hepatitis C, a disease that afflicts more than 3 million

people in the United States alone, and 170 million worldwide.

• The ADVANCE trial will enroll 1,050 treatment-naive genotype 1 HCV patients

and will evaluate two 24-week telaprevir-based regimens in comparison to a

48-week control arm.

• The primary endpoint of the study is sustained viral response (SVR), defined

as undetectable HCV RNA (

_________________________________________________________________

Climb to the top of the charts! Play the word scramble challenge with star

power.

http://club.live.com/star_shuffle.aspx?icid=starshuffle_wlmailtextlink_jan